CanDoIT is one of the largest European research programmes led by Centrale Lille. Involving 18 research teams (academic and industrial) in 5 European countries (France, Italy, Germany, Slovenia and the UK), it aims to develop multimodal biosensors for individualised monitoring of the therapeutic response to treatments administered for breast cancer. Ultimately, the partners plan to adapt the biosensor technology developed to other pathologies.
The 4-year project will involve around fifty researchers and the recruitment of 12 doctoral students from the partner institutions to start their theses in autumn 2024. To this end, the Doctoral Candidate recruitment event of the Marie Skłodowska-Curie ‘Doctoral Network’ CanDoIt European excellence project, for which Centrale Lille is the coordinating institution, will take place on 9 and 10 July 2024. This project is jointly coordinated by Abdelkrim Talbi and Philippe Pernod, University Professors at Centrale Lille who carry out their research at IEMN 8520″.
The CanDoIt project
Aims:
- To develop multimodal biosensors for individualised monitoring of the therapeutic response to treatments administered for breast cancer.
- Eventually adapt this technology to other pathologies.
Partnership :
- Mobilisation of 18 research teams (academic and industrial) in 5 European countries (France, Italy, Germany, Slovenia and the UK).
- Budget: €2.65m, funded by Horizon Europe and UK Research and Innovation for the recruitment and training of future PhDs associated with the project.
Technologies :
- Biosensors detecting cancer biomarkers in biofluids.
- Personalised, non-intrusive monitoring of therapeutic response.
- Collaboration between biologists, chemists, sensor engineers and AI experts.
- Preclinical and clinical trials at the Oscar Lambret Centre in Lille.
For more information about the project, please contact
Philippe Pernod
Abdelkrim Talbi